pharma · Epidermolysis Bullosa Simplex · INM
InMed Pharmaceuticals
InMed Pharmaceuticals is a pharma organization headquartered in Vancouver, CA. It trades on NYSE under ticker INM. Primary therapeutic focus areas include Epidermolysis Bullosa Simplex. NovaPharmaNews links 1 clinical pr
Vancouver, CA HQ
19 Employees
Public company Type
INM · NYSE Ticker
Company details
- Status
- Public
- HQ
- Vancouver, CA
- Employees
- 19
- Programs
- 1
- Drugs
- 0
- Patents
- 15
INM-755 (cannabinol) cream
Phase 2 · small molecule · Epidermolysis Bullosa Simplex
INM-755 (cannabinol) cream for Epidermolysis Bullosa Simplex is a Phase 2 program (small_molecule) at InMed Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code 755-201-EB
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- InMed Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Epidermolysis Bullosa Simplex
- Status
- completed
- Trials
- 1